A recent article is titled “Determination of Bone Age in Pediatric Patients with Crohn’s Disease Should Become Part of Routine Care” (Inflamm Bowel Dis 2013; 19: 61-65). (Thanks to Ben Gold for suggesting this reference.)
Does the study merit the authors’ conclusion that ‘determination of bone age (BA) should become the standard of care in pediatric Crohn’s disease (CD) patients, allowing clinically meaningful interpretation of growth…leading to improved treatment recommendations?’
No. This small study (n=49, 84% Caucasian) simply showed that a lot of pediatric CD patients have a delayed bone age. This is not a novel finding.
Specifically, the mean BA Z score was -1.40 ± 1.5 in this population and 41% had a BA Z score of < -2.0. This cross-sectional study was conducted between 2007-2009. Patients were consecutively approached for enrollment during this time period.
Clinical factors associated with delayed bone age included Caucasian race, Tanner stage 1-3, history of steroid exposure, colonic disease location, azathioprine/6-mercaptopurine usage, and female sex. Interestingly, these variables are not entirely consistent with prior studies in which male sex was associated with delayed bone age.
The reason why the conclusion is a far-reach is that there is no data in the study showing how bone age influences any clinical decision-making in these patients. There is no information on cost-effectiveness of their proposed “standard of care.” There is no longitudinal data to suggest that the delayed BA or the recognition of a delayed BA resulted in a different outcome.
Many pediatric patients with CD have delayed BA and some may benefit from a BA determination. I think extrapolating a much broader conclusion from this study is not warranted.